Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inovio Pharmaceuticals has got $733,438 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA) related to three of the company's projects, including the Phase II clinical trial of VGX-3100.
Subscribe to our email newsletter
VGX-3100 is a therapeutic vaccine for cervical dysplasia and cancer.
The grant will also support Inovio Pharma’s development projects for Syncon universal flu and dengue vaccines.
The PPACA provides small and mid-sized biotech, pharmaceutical and medical device companies with up to a 50% tax credit for investments in qualified therapeutic discoveries for tax years 2009 and 2010, or a grant for the same amount tax-free.